       Document 0144
 DOCN  M9640144
 TI    Pharmacokinetics of zidovudine and didanosine during combination
       therapy.
 DT    9604
 AU    Morse GD; Shelton MJ; Ho M; Bartos L; DeRemer M; Ragni M; Department of
       Pharmacy Practice, State University of New York at; Buffalo 14260, USA.
 SO    Antiviral Res. 1995 Aug;27(4):419-24. Unique Identifier : AIDSLINE
       MED/96049788
 AB    While the combination of zidovudine and didanosine is used in
       HIV-infected patients with more advanced disease, the possibility of a
       pharmacokinetic interaction between these two drugs remains
       controversial. Zidovudine doses of 50, 100, and 200 mg, combined with
       67, 167, and 250 mg of didanosine were evaluated in 11 asymptomatic
       HIV-infected patients after receiving 24 weeks of combination therapy in
       AIDS Clinical Trials Group protocol 143. The pharmacokinetic parameters
       of zidovudine and didanosine were similar to those obtained with each
       drug given as monotherapy in other previously published studies. The
       renal clearance and urinary recovery of glucuronidated zidovudine was
       reduced when zidovudine was given in combination with didanosine,
       possibly due to competition for renal tubular secretion. These data
       suggest that no clinically important pharmacokinetic interaction occurs
       when zidovudine and didanosine are given together.
 DE    Adult  Didanosine/*PHARMACOKINETICS/THERAPEUTIC USE  Drug Therapy,
       Combination  Female  Human  HIV Infections/*DRUG THERAPY  Male  Support,
       Non-U.S. Gov't  Support, U.S. Gov't, P.H.S.
       Zidovudine/*PHARMACOKINETICS/THERAPEUTIC USE  CLINICAL TRIAL  CLINICAL
       TRIAL, PHASE I  CLINICAL TRIAL, PHASE II  JOURNAL ARTICLE  RANDOMIZED
       CONTROLLED TRIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

